Editas Medicine, Inc. – LSE:0IFK.L
Editas Medicine stock price today
Editas Medicine stock price monthly change
Editas Medicine stock price quarterly change
Editas Medicine stock price yearly change
Editas Medicine key metrics
Market Cap | 105.69M |
Enterprise value | N/A |
P/E | N/A |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | -2.1 |
Revenue | 69.40M |
EBITDA | -177.19M |
Income | -166.13M |
Revenue Q/Q | -88.47% |
Revenue Y/Y | 204.53% |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | -255.29% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeEditas Medicine stock price history
Editas Medicine stock forecast
Editas Medicine financial statements
| Jun 2023 | 2.88M | -40.29M | -1395.57% |
|---|---|---|---|
| Sep 2023 | 5.33M | -45.01M | -843.68% |
| Dec 2023 | 60.04M | -18.87M | -31.43% |
| Mar 2024 | 1.13M | -61.95M | -5458.15% |
| Sep 2025 | 5.03M | -54.07M | -1074.34% |
|---|---|---|---|
| Dec 2025 | 11.83M | -50.14M | -423.73% |
| Mar 2026 | 1.81M | -59.30M | -3274.13% |
| Jun 2026 | 1.92M | -59.15M | -3080.19% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 541953000 | 142.03M | 26.21% |
|---|---|---|---|
| Sep 2023 | 504650000 | 144.18M | 28.57% |
| Dec 2023 | 499153000 | 150.05M | 30.06% |
| Mar 2024 | 440347000 | 145.94M | 33.14% |
| Jun 2023 | -38.71M | 12.98M | 117.52M |
|---|---|---|---|
| Sep 2023 | -35.45M | -102.82M | 0 |
| Dec 2023 | -22.24M | 62.84M | 514K |
| Mar 2024 | -49.87M | -4.74M | 192K |
Editas Medicine alternative data
| Aug 2023 | 226 |
|---|---|
| Sep 2023 | 226 |
| Oct 2023 | 226 |
| Nov 2023 | 226 |
| Dec 2023 | 226 |
| Jan 2024 | 226 |
| Feb 2024 | 226 |
| Mar 2024 | 265 |
| Apr 2024 | 265 |
| May 2024 | 265 |
| Jun 2024 | 265 |
| Jul 2024 | 265 |
Editas Medicine other data
| Insider | Compensation |
|---|---|
Ms. Cynthia L. Collins M.B.A. (1958) Pres, Chief Executive Officer & Director | $1,140,000 |
| Dr. Charles Albright (1958) Executive Vice President & Chief Scientific Officer | $732,790 |
Mr. Mark J. Mullikin Senior Director of Fin. & Investor Relations | |
Mr. Harry R. Gill III Senior Vice President of Operations | |
Dr. Feng Zhang Co-Founder & Scientific Advisory Board Member | |
Dr. David R. Liu Co-Founder & Scientific Advisory Board Member | |
Dr. George M. Church Co-Founder & Scientific Advisory Board Member | |
Dr. J. Keith Joung Co-Founder & Scientific Advisory Board Member | |
Ms. Charlene Stern Senior Vice President & Chief Legal Officer | |
| Ms. Michelle Robertson Chief Financial Officer, Principal Accounting Officer, Treasurer & Assistant Sec. |
-
What's the price of Editas Medicine stock today?
One share of Editas Medicine stock can currently be purchased for approximately $27.14.
-
When is Editas Medicine's next earnings date?
Unfortunately, Editas Medicine's (0IFK.L) next earnings date is currently unknown.
-
Does Editas Medicine pay dividends?
No, Editas Medicine does not pay dividends.
-
How much money does Editas Medicine make?
Editas Medicine has a market capitalization of 105.69M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 296.32% to 78.12M US dollars.
-
What is Editas Medicine's stock symbol?
Editas Medicine, Inc. is traded on the LSE under the ticker symbol "0IFK.L".
-
What is Editas Medicine's primary industry?
Company operates in the Healthcare sector and Medical - Pharmaceuticals industry.
-
How do i buy shares of Editas Medicine?
Shares of Editas Medicine can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Editas Medicine's key executives?
Editas Medicine's management team includes the following people:
- Ms. Cynthia L. Collins M.B.A. Pres, Chief Executive Officer & Director(age: 67, pay: $1,140,000)
- Dr. Charles Albright Executive Vice President & Chief Scientific Officer(age: 67, pay: $732,790)
- Mr. Mark J. Mullikin Senior Director of Fin. & Investor Relations
- Mr. Harry R. Gill III Senior Vice President of Operations
- Dr. Feng Zhang Co-Founder & Scientific Advisory Board Member
- Dr. David R. Liu Co-Founder & Scientific Advisory Board Member
- Dr. George M. Church Co-Founder & Scientific Advisory Board Member
- Dr. J. Keith Joung Co-Founder & Scientific Advisory Board Member
- Ms. Charlene Stern Senior Vice President & Chief Legal Officer
- Ms. Michelle Robertson Chief Financial Officer, Principal Accounting Officer, Treasurer & Assistant Sec.
-
Is Editas Medicine founder-led company?
Yes, Editas Medicine is a company led by its founders Dr. Feng Zhang, Dr. David R. Liu, Dr. George M. Church and Dr. J. Keith Joung.
-
How many employees does Editas Medicine have?
As Jul 2024, Editas Medicine employs 265 workers.
-
When Editas Medicine went public?
Editas Medicine, Inc. is publicly traded company for more then 7 years since IPO on 29 Jan 2018.
-
What is Editas Medicine's official website?
The official website for Editas Medicine is editasmedicine.com.
-
Where are Editas Medicine's headquarters?
Editas Medicine is headquartered at 11 Hurley Street, Cambridge, MA.
-
How can i contact Editas Medicine?
Editas Medicine's mailing address is 11 Hurley Street, Cambridge, MA and company can be reached via phone at +61 74019000.
Editas Medicine company profile:
Editas Medicine, Inc.
editasmedicine.comLSE
265
Medical - Pharmaceuticals
Healthcare
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has an early discovery program to develop a therapy to treat a neurological disease. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and research collaboration with Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease, as well as research collaboration with AskBio. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Cambridge, MA 02141
:
ISIN: US28106W1036
:
